Summary

The China mammography market size is expected to grow from USD 121.25 million in 2024 to USD 185.97 million by 2029, at a CAGR of 11.24% during the forecast period (2024-2029).

Key Highlights

• COVID-19 significantly impacted the market studied due to the closure of clinics and diagnostic facilities, causing delays in early diagnosis that had an immediate effect on cancer patients. According to the study published in the Chinese Journal of General Surgery in February 202urgery in February 2020, patients with breast tumors had particularly low immunity and were susceptible to the new coronavirus. The low immunity among breast cancer patients for COVID-19 led to a decrease in attendees for breast cancer screening in China. However, during the late pandemic, the market saw a surge in screening for lagging cases, and post-pandemic, the market attained pace, thereby showing significant growth over the forecast period.
• Factors such as the growing incidences of breast cancer, technological advancements in the field of breast imaging, and the investment from various organizations in breast cancer screening campaigns are boosting the growth of the market studied. Additionally, according to news published in Science and Technology Daily in March 2021, breast cancer patients in China will reach 2.5 million in 2021, of which men account for about 1%. Furthermore, data from Globocan 2020 published by the International Agency for Research on Cancer shows that there were 416,000 new instances of breast cancer in China in 2020, with a projected increase to 481,000 cases by 2040. The number of patients looking for mammograms at hospitals across China is anticipated to increase as breast cancer incidence rises, thereby accelerating market growth.
• The increase in awareness of breast cancer and access to mammography screening services is another factor contributing to the market growth. For instance, according to an announcement made in July 2021 by Shenzhen Anke High-tech Co. Ltd, a manufacturer of mammography equipment, the isolated Chinese Qinghai-Tibet plateau will have access to mammography services. Thus, it was anticipated that more people would go for breast scans at hospitals equipped with mammography equipment, thereby fuelling market growth.
• Thus, factors such as the rising incidence of breast cancer and rising initiatives from the key market players are anticipated to drive market growth. However, the risk of adverse effects from radiation exposure and lack of proper reimbursement for breast cancer screening are expected to hinder the market growth.

China Mammography Market Trends

Specialty Clinics Segment is Expected to Hold a Significant Market Share Over the Forecast Period

• The high prevalence of breast cancer cases and strategic initiatives by the major clinics are expected to boost market growth and large investments in healthcare expenditure. Additionally, awareness programs are also expected to boost market growth.
• According to the news published in March 2021, 400,000 Chinese women will develop breast cancer every year. Thus, the number of individuals requesting mammography screenings at clinics across China is anticipated to climb as breast cancer cases rise. This is anticipated to accelerate the segment expansion over the forecast period.
• Furthermore, the launch of breast clinic services in China is expected to drive segment growth over the forecast period due to the increased adoption of mammography services. For instance, in June 2021, Jiahui Breast Institute, a breast clinic, offered breast health outpatient services, including breast health screening through mammograms.
• Therefore, it is anticipated that the aforementioned improvements will further enhance the market growth in this sector.

Breast Tomosynthesis is Expected to Grow with a Healthy CAGR in the Market Studied Over the Forecast Period.

• Breast tomosynthesis is a technologically advanced form of breast imaging that decreases the confounding effect of overlapping tissue and helps in improved lesion detection, characterization, and localization of tumors effectively.
• Based on advancements in both screening and diagnostic imaging outcomes, digital breast tomosynthesis (DBT) is becoming the standard for breast imaging. The additional information obtained from the tomosynthesis decreases the confounding effect of overlapping tissue, allowing for improved lesion detection, characterization, and localization. Also, compared to only using two-dimensional full-field digital mammography for imaging, the reconstructed DBT data set's quasi-three-dimensional information enables a more effective imaging work-up.
• According to the study published in the British Journal of Radiology in March 2021 in China, in younger women with thicker breasts, full-field digital mammography (FFDM) has limited sensitivity for malignancy. Therefore, Digital breast tomosynthesis (DBT) can reduce the risk of cancer being obscured by overlying tissue in such instances. The diverse advantages of DBT in patients with thick breast is expected to propel the segment growth over the forecast period.
• Rising awareness among the people due to the campaigns is expected to drive the segment studied over the forecast period. For instance, in March 2021, Beijing hosted the 5th Breast Cancer Endowment Management Chief Expert Forum and the 2021 China Cancer Health Management Conference. During the event, the Healthy China Breast Cancer Key Decade Action (HC-ABC Project) was formally launched at the conference, focusing on standardizing diagnosis and treatment to improve breast cancer patient survival over the next ten years. This will be achieved by enhancing homogenous diagnosis and treatment as well as standardized diagnosis and therapy. During the projected period, initiatives like these are anticipated to enhance segment growth since more patients may request standard mammography screening such as DBT.
• Therefore, the rising awareness of breast cancer screening and the rising benefits of DBT are the factors anticipated to drive the segment growth.

China Mammography Industry Overview

China's mammography market is moderately competitive and consists of several major players. The factors owing to the completion include the rising initiatives from the market players, such as the launch of products and conducting brand awareness programs. Some of the companies that are currently operating in the market are GE Healthcare, Fujifilm Holdings Corporation, Siemens Healthineers AG, Carestream Health Inc., and Koninklijke Philips NV, among others.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

ページTOPに戻る

Table of Contents

1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Burden of Breast Cancer
4.2.2 Technological Advancements in the Field of Breast Imaging
4.2.3 Investment from Various Organizations in Breast Cancer Screening Campaigns
4.3 Market Restraints
4.3.1 Risk of Adverse Effects from Radiation Exposure
4.3.2 Lack of Proper Reimbursement for Breast Cancer Screening
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD)
5.1 By Product Type
5.1.1 Digital Systems
5.1.2 Analog Systems
5.1.3 Breast Tomosynthesis
5.1.4 Other Product Types
5.2 By End-User
5.2.1 Hospitals
5.2.2 Specialty Clinics
5.2.3 Diagnostic Centers

6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Carestream Health Inc.
6.1.2 Trivitron Healthcare
6.1.3 Koninklijke Philips NV
6.1.4 Fujifilm Holdings Corporation
6.1.5 Canon Inc. (Canon Medical Systems Corporation)
6.1.6 GE Healthcare
6.1.7 General Medical Merate SpA
6.1.8 Hologic Inc.
6.1.9 Konica Minolta Inc.
6.1.10 Siemens Healthineers AG

7 MARKET OPPORTUNITIES AND FUTURE TRENDS